Method of treating parkinson's disease comprising administering deferoxamine (DFO) to the upper one-third of the nasal cavity
Methods and pharmaceutical compositions for treating neurodegeneration in patients diagnosed with Parkinson's Disease. Intranasal therapeutic agents, e.g., chelators, are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal systemic side effects. Therapeutic agents include those substances that interact with iron and/or copper such as metal chelators generally, including but not limited to iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO).
1. A method to treat neurodegeneration of a patient diagnosed with Parkinson's disease comprising: administering at least one effective dose of deferoxamine (DFO) to the upper one-third of the patient's nasal cavity, wherein the at least one effective dose of DFO is 0.0001 to 1.0 mg/kg;
thereby enabling the at least one effective dose of DFO to bypass the patient's blood-brain barrier and delivering the at least one effective dose of DFO to the patient's central nervous system; and
treating the neurodegeneration of the patient diagnosed with Parkinson's disease.
2. The method of claim 1 further comprising the at least one effective dose of DFO having a volume of 0.015 to 1.0 ml.
3. The method of claim 1 wherein the dose of DFO is 0.005 to 1.0 mg/kg.
4. The method of claim 1 , further comprising administering the at least one dose of DFO until the concentration of DFO in the patient's brain is within the range of 0.1 nM to 50 μM.
5. The method of claim 1 , wherein the dose of DFO is administered to the upper one-third of the patient's nasal cavity as a liquid spray.
6. The method of claim 1 , wherein the dose of DFO is administered to the upper one-third of the patient's nasal cavity as a powdered spray.
7. The method of claim 1 , wherein the dose of DFO is administered to the upper one-third of the patient's nasal cavity as nose drops.
8. The method of claim 1 , wherein the dose of DFO is administered to the upper one-third of the patient's nasal cavity as a gel.
9. The method of claim 1 , wherein the dose of DFO is administered to the upper one-third of the patient's nasal cavity as an ointment.
10. The method of claim 1 , wherein the treated neurodegeneration is caused by Parkinson's disease.
11. A method to treat neurodegeneration of a patient diagnosed with Parkinson's disease comprising:
administering at least one effective dose of a copper chelator to the upper one-third of the patient's nasal cavity, wherein the at least one effective dose of the metal chelator is 0.0001 to 1.0 mg/kg;
thereby enabling the at least one effective dose of the copper chelator to bypass the patient's blood-brain barrier and delivering the at least one effective dose of the copper chelator to the patient's central nervous system; and treating the neurodegeneration of the patient diagnosed with Parkinson's disease.